ABN-AMRO is recommending Elan as a good buy for investors. The stockbroker is forecasting that the shares could rise from current levels of around $78.56 (€71.42) to $100 within 12 months. The buy recommendation is based on stronger than expected earnings prospects for the pharmaceutical giant and an acceleration in drug approvals this year.